Download MendeleyIdentification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.
Fairhurst, R.A., Furet, P., Imbach-Weese, P., Stauffer, F., Rueeger, H., McCarthy, C., Ripoche, S., Oswald, S., Arnaud, B., Jary, A., Maira, M., Schnell, C., Guthy, D.A., Wartmann, M., Kiffe, M., Desrayaud, S., Blasco, F., Widmer, T., Seiler, F., Gutmann, S., Knapp, M., Caravatti, G.(2022) J Med Chem 65: 8345-8379
- PubMed: 35500094
- DOI: https://doi.org/10.1021/acs.jmedchem.2c00267
- Primary Citation of Related Structures:
7R26, 7R2B, 7TZ7 - PubMed Abstract:
Balanced pan-class I phosphoinositide 3-kinase inhibition as an approach to cancer treatment offers the prospect of treating a broad range of tumor types and/or a way to achieve greater efficacy with a single inhibitor. Taking buparlisib as the starting point, the balanced pan-class I PI3K inhibitor 40 (NVP-CLR457) was identified with what was considered to be a best-in-class profile. Key to the optimization to achieve this profile was eliminating a microtubule stabilizing off-target activity, balancing the pan-class I PI3K inhibition profile, minimizing CNS penetration, and developing an amorphous solid dispersion formulation. A rationale for the poor tolerability profile of 40 in a clinical study is discussed.
Organizational Affiliation:
Novartis Institutes for BioMedical Research, Basel CH-4002, Switzerland.
